Bayer (BAYN GY) files a lawsuit against Johnson & Johnson (JNJ) and Janssen Biotech; Says J&J claims on NUBEQUA are deeply flawed and are intentionally aimed at boosting sales of ERLEADA, with Bayer seeking injunction and damages

Bayer (BAYN GY) files a lawsuit against Johnson & Johnson (JNJ) and Janssen Biotech; Says J&J claims on NUBEQUA are deeply flawed and are intentionally aimed at boosting sales of ERLEADA, with Bayer seeking injunction and damages.

Bayer's lawsuit against Johnson & Johnson highlights significant tensions in the pharmaceutical sector, particularly regarding the competitive dynamics between their products, NUBEQUA and ERLEADA. This legal action could impact both companies' reputations and sales strategies, while raising questions about market positions and potential regulatory responses, especially if Bayer seeks damages and an injunction, which may limit J&J's marketing practices.